Pathology: la/mBC - HER2 positive - 2nd Line (L2); la/mBC - HR-positive - 1st line (L1);
| la/mBC - HER2 positive - 2nd Line (L2) | la/mBC - HR-positive - 1st line (L1) | |||||
| WJOG6110B/ELTOP, 2018 | EGF104900, 2010 | CALGB 40302, 2014 | EGF30008 (all population), 2009 | EGF30008 (HER2-positive), 2009 | ||
| lapatinib plus letrozole | 2 | T1 | T1 | |||
| lapatinib plus capecitabine | 1 | T1 | ||||
| lapatinib plus fulvestrant | 1 | T1 | ||||
| lapatinib plus trastuzumab | 1 | T1 | ||||
| trastuzumab plus capecitabine | 0 | T0 | ||||
| fulvestrant | 0 | T0 | ||||
| lapatinib | 0 | T0 | ||||
| letrozole | 0 | T0 | T0 | |||